Glycosaminoglycan mimetics: a therapeutic approach to cerebral amyloid angiopathy

Amyloid deposits characteristic of cerebral amyloid angiopathy lead to vessel rupture and intracerebral hemorrhage. Proteoglycans associate with the amyloid fibril deposits and are thought to play a role in the polymerization of amyloid proteins and the propagation of the deposition process. A serie...

Full description

Saved in:
Bibliographic Details
Published in:Amyloid 2001-07, Vol.8 Suppl 1, p.28
Main Authors: Gervais, F, Chalifour, R, Garceau, D, Kong, X, Laurin, J, Mclaughlin, R, Morissette, C, Paquette, J
Format: Article
Language:English
Subjects:
Amyloid beta-Peptides - chemistry
Amyloid beta-Peptides - drug effects
Amyloid beta-Peptides - metabolism
Animals
Blood-Brain Barrier
Cells, Cultured
Cerebral Amyloid Angiopathy - drug therapy
Cerebral Amyloid Angiopathy - metabolism
Circular Dichroism
Glycosaminoglycans - therapeutic use
Humans
In Vitro Techniques
Kinetics
Mice
Microscopy, Electron
Molecular Mimicry
Rats
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Amyloid deposits characteristic of cerebral amyloid angiopathy lead to vessel rupture and intracerebral hemorrhage. Proteoglycans associate with the amyloid fibril deposits and are thought to play a role in the polymerization of amyloid proteins and the propagation of the deposition process. A series of low molecular weight anionic compounds was developed to mimic the glycosaminoglycan moieties of these proteoglycans. These compounds were tested in different in vitro systems to determine their anti-Abeta amyloid activity. Specific compounds were identified as being anti-fibrillogenic and protective against Abeta-induced cvtotoxicity. Such compounds also did not show intrinsic cellular toxicity could cross the blood-brain barrier (BBB) in vivo, and showed a good safety profile following chronic' exposure. Molecules showing an anti-amyloid profile combined with the ability to cross the BBB represent promising therapeutics for CAA.
ISSN:1350-6129